{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:28:46Z","timestamp":1791527326346,"version":"4.3.4"},"reference-count":109,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.tips.2025.08.012","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:35:16Z","timestamp":1758022516000},"page":"1130-1143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Emerging mechanisms of psilocybin-induced neuroplasticity"],"prefix":"10.1016","volume":"46","author":[{"given":"Sonia","family":"Sonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Pendin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Comai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2023-0749","authenticated-orcid":false,"given":"Andrea","family":"Mattarei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.08.012_bb0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41386-023-01656-7","article-title":"Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism","volume":"49","author":"Mitchell","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1391689","article-title":"In vitro and in vivo metabolism of psilocybin\u2019s active metabolite psilocin","volume":"15","author":"Thomann","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0015","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.08.012_bb0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2025.08.012_bb0025","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0030","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tips.2025.08.012_bb0035","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.08.012_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0045","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103149","article-title":"Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial","volume":"82","author":"Rieser","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tips.2025.08.012_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae057","article-title":"Psychedelics for the treatment of obsessive\u2013compulsive disorder: efficacy and proposed mechanisms","volume":"27","author":"Collins","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0060","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/1877718X241312604","article-title":"Psilocybin-assisted psychotherapy for Parkinson\u2019s disease without depression: a case-report","volume":"15","author":"Fleury","year":"2025","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.tips.2025.08.012_bb0065","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41386-025-02097-0","article-title":"Psilocybin therapy for mood dysfunction in Parkinson\u2019s disease: an open-label pilot trial","volume":"50","author":"Bradley","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0070","article-title":"Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial","volume":"6","author":"Aday","year":"2025","journal-title":"Front. Pain Res. (Lausanne)"},{"key":"10.1016\/j.tips.2025.08.012_bb0075","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study","volume":"29","author":"Peck","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.08.012_bb0080","series-title":"Antidepressants","first-page":"135","article-title":"Selective serotonin reuptake inhibitors","volume":"Vol 250","author":"Lochmann","year":"2019"},{"key":"10.1016\/j.tips.2025.08.012_bb0085","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.08.012_bb0090","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2025.08.012_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/02698811241249436","article-title":"Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice","volume":"38","author":"Zhao","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0100","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41586-025-08813-6","article-title":"Psilocybin\u2019s lasting action requires pyramidal cell types and 5-HT2A receptors","volume":"642","author":"Shao","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.08.012_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41398-025-03308-4","article-title":"Intravenous psilocybin induces dose-dependent changes in functional network organization in rat cortex","volume":"15","author":"Silverstein","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","article-title":"Psilocybin desynchronizes the human brain","volume":"632","author":"Siegel","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.08.012_bb0115","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.08.012_bb0120","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1038\/s41467-022-33578-1","article-title":"Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain\u2019s control energy landscape","volume":"13","author":"Singleton","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.08.012_bb0125","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41467-022-28735-5","article-title":"Associations between alcohol consumption and gray and white matter volumes in the UK Biobank","volume":"13","author":"Daviet","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.08.012_bb0130","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/mp.2016.60","article-title":"Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group","volume":"22","author":"Schmaal","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41398-025-03226-5","article-title":"Individualized gray matter morphological abnormalities unveil two neuroanatomical obsessive-compulsive disorder subtypes","volume":"15","author":"Wen","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab269","article-title":"Brain atrophy progression in Parkinson\u2019s disease is shaped by connectivity and local vulnerability","volume":"3","author":"Tremblay","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.tips.2025.08.012_bb0145","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2020.19","article-title":"Lower gray matter volumes of frontal lobes and insula in adolescents with anorexia nervosa restricting type: findings from a brain morphometry study","volume":"63","author":"Curzio","year":"2020","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/acs.biochem.1c00812","article-title":"Biochemical mechanisms underlying psychedelic-induced neuroplasticity","volume":"61","author":"Olson","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.tips.2025.08.012_bb0155","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","article-title":"Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics","volume":"42","author":"Aleksandrova","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0160","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","article-title":"Psychedelics reopen the social reward learning critical period","volume":"618","author":"Nardou","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.08.012_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.710004","article-title":"Critical period plasticity as a framework for psychedelic-assisted psychotherapy","volume":"15","author":"Lepow","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0170","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","article-title":"The neural basis of psychedelic action","volume":"25","author":"Kwan","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0175","doi-asserted-by":"crossref","first-page":"7472","DOI":"10.1523\/JNEUROSCI.1384-23.2023","article-title":"Beyond the 5-HT 2A receptor: classic and nonclassic targets in psychedelic drug action","volume":"43","author":"Cameron","year":"2023","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0180","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.08.012_bb0195","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential","volume":"14","author":"Wallach","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.08.012_bb0200","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.08.012_bb0205","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41398-023-02456-9","article-title":"Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder","volume":"13","author":"Singh","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.113093","article-title":"Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice","volume":"401","author":"Odland","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.tips.2025.08.012_bb0215","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41386-024-01794-6","article-title":"Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?","volume":"49","author":"Sekssaoui","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0220","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0225","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s00210-023-02778-x","article-title":"Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL\/6J male mice","volume":"397","author":"Takaba","year":"2024","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0230","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","article-title":"5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines","volume":"14","author":"Cameron","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0235","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.08.012_bb0240","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1021\/acschemneuro.2c00637","article-title":"Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin","volume":"14","author":"Davoudian","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0245","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0269881120959614","article-title":"Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin","volume":"35","author":"Jefsen","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.640241","article-title":"Low doses of psilocybin and ketamine enhance motivation and attention in poor performing rats: evidence for an antidepressant property","volume":"12","author":"Higgins","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0255","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00213-022-06092-x","article-title":"Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents","volume":"239","author":"Jaster","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0260","article-title":"Functional unblinding in pivotal studies and the future of psychedelic medicine","volume":"85","author":"Rosenbaum","year":"2024","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0265","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-2008-1038191","article-title":"Hallucinogen-induced psychological disorders","volume":"76","author":"Hermle","year":"2008","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"10.1016\/j.tips.2025.08.012_bb0270","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.tips.2023.09.012","article-title":"Ligand selectivity hotspots in serotonin GPCRs","volume":"44","author":"Simon","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0275","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","article-title":"Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor","volume":"182","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.08.012_bb0280","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1038\/s41467-025-57956-7","article-title":"The structural diversity of psychedelic drug actions revealed","volume":"16","author":"Gumpper","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.08.012_bb0285","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/1873-3468.15099","article-title":"Molecular insights into the modulation of the 5HT2A receptor by serotonin, psilocin, and the G protein subunit Gq\u03b1","volume":"599","author":"Viohl","year":"2025","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tips.2025.08.012_bb0290","first-page":"140914","article-title":"The molecular basis of the antidepressant action of the magic mushroom extract, psilocin","volume":"2023","author":"Zanjani","year":"1871","journal-title":"Biochim. Biophys. Acta (BBA) Proteins Proteom."},{"key":"10.1016\/j.tips.2025.08.012_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112203","article-title":"A non-hallucinogenic LSD analog with therapeutic potential for mood disorders","volume":"42","author":"Lewis","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.08.012_bb0300","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41586-022-05258-z","article-title":"Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity","volume":"610","author":"Kaplan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.08.012_bb0305","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2416106122","article-title":"Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential","volume":"122","author":"Tuck","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1233743","article-title":"The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice","volume":"10","author":"Pogorelov","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0315","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.08.012_bb0320","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.cell.2021.03.043","article-title":"Psychedelic-inspired drug discovery using an engineered biosensor","volume":"184","author":"Dong","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.08.012_bb0325","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/acs.jmedchem.9b01404","article-title":"Identification of psychoplastogenic N,N-dimethylaminoisotryptamine (isoDMT) analogues through structure\u2013activity relationship studies","volume":"63","author":"Dunlap","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.08.012_bb0330","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41386-023-01725-x","article-title":"Antidepressants enter cells, organelles, and membranes","volume":"49","author":"Blumenfeld","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaw3122","article-title":"Interclass GPCR heteromerization affects localization and trafficking","volume":"13","author":"Toneatti","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tips.2025.08.012_bb0340","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1523\/JNEUROSCI.1665-10.2010","article-title":"Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a \u03b2-arrestin2\/Src\/Akt signaling complex in vivo","volume":"30","author":"Schmid","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0345","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tibs.2024.10.006","article-title":"Endomembrane GPCR signaling: 15 years on, the quest continues","volume":"50","author":"Calebiro","year":"2025","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202300123","article-title":"Location bias: a \u2018hidden variable\u2019 in GPCR pharmacology","volume":"45","author":"Eiger","year":"2023","journal-title":"Bioessays"},{"key":"10.1016\/j.tips.2025.08.012_bb0355","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/acsptsci.0c00065","article-title":"Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth","volume":"4","author":"Ly","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0360","doi-asserted-by":"crossref","first-page":"E4485","DOI":"10.1073\/pnas.1503766112","article-title":"Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles","volume":"112","author":"Tucker","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0365","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881120965908","article-title":"Presynaptic vesicular accumulation is required for antipsychotic efficacy in psychotic-like rats","volume":"35","author":"Uzuneser","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0370","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1038\/s41598-022-14512-3","article-title":"Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls","volume":"12","author":"Rootman","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.08.012_bb0375","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41398-022-02039-0","article-title":"Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study","volume":"12","author":"Cavanna","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0380","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41398-022-02103-9","article-title":"Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice","volume":"12","author":"Fadahunsi","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2025.06.012","article-title":"The polypharmacology of psychedelics reveals multiple targets for potential therapeutics","author":"Jain","year":"2025","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2025.08.012_bb0390","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2025.08.012_bb0395","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/bs.pbr.2020.11.002","article-title":"Cortical influences of serotonin and glutamate on layer V pyramidal neurons","volume":"261","author":"Marek","year":"2021","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.tips.2025.08.012_bb0400","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tins.2020.11.008","article-title":"A dendrite-focused framework for understanding the actions of ketamine and psychedelics","volume":"44","author":"Savalia","year":"2021","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0405","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41586-021-03376-8","article-title":"Structural insights into the lipid and ligand regulation of serotonin receptors","volume":"592","author":"Xu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.08.012_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111211","article-title":"Molecular insights into the regulation of constitutive activity by RNA editing of 5HT2C serotonin receptors","volume":"40","author":"Gumpper","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.08.012_bb0415","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/FBP.0b013e3282f62cb2","article-title":"Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice","volume":"19","author":"Bruins Slot","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0420","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41586-024-07403-2","article-title":"Structural pharmacology and therapeutic potential of 5-methoxytryptamines","volume":"630","author":"Warren","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.08.012_bb0425","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.767","article-title":"The 5-HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: a pilot study in treatment-seeking individuals","volume":"9","author":"Campbell","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.tips.2025.08.012_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1074633","article-title":"Psilocybin sex-dependently reduces alcohol consumption in C57BL\/6J mice","volume":"13","author":"Alper","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0435","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.vascn.2013.12.004","article-title":"Safety Pharmacology assessment of drugs with biased 5-HT2B receptor agonism mediating cardiac valvulopathy","volume":"69","author":"Cavero","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.tips.2025.08.012_bb0440","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tibs.2024.02.001","article-title":"TrkB transmembrane domain: bridging structural understanding with therapeutic strategy","volume":"49","author":"Enkavi","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2020.101983","article-title":"Brain-derived neurotrophic factor blood levels after electroconvulsive therapy in patients with major depressive disorder: a systematic review and meta-analysis","volume":"51","author":"Luan","year":"2020","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.tips.2025.08.012_bb0450","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","article-title":"Antidepressant drugs act by directly binding to TRKB neurotrophin receptors","volume":"184","author":"Casarotto","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.08.012_bb0455","doi-asserted-by":"crossref","first-page":"9316","DOI":"10.1038\/s41467-024-53710-7","article-title":"Structural basis for the transmembrane signaling and antidepressant-induced activation of the receptor tyrosine kinase TrkB","volume":"15","author":"Kot","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.08.012_bb0460","article-title":"Robust methods for quantifying neuronal morphology and molecular signaling reveal that psychedelics do not induce neuroplasticity","author":"Boltaev","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.tips.2025.08.012_bb0465","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tips.2025.08.012_bb0470","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0475","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/appi.ajp.20220835","article-title":"Antidepressant effects of psilocybin in the absence of psychedelic effects","volume":"180","author":"Rosenblat","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0480","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220979120","article-title":"Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief","volume":"120","author":"Hegron","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.tips.2025.08.012_bb0485","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1111\/bph.16248","article-title":"G\u03b1q signalling from endosomes: a new conundrum","volume":"182","author":"Daly","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0490","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77455","article-title":"BDNF\/TrkB signaling endosomes in axons coordinate CREB\/mTOR activation and protein synthesis in the cell body to induce dendritic growth in cortical neurons","volume":"12","author":"Moya-Alvarado","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.tips.2025.08.012_bb0495","series-title":"The Plastic Brain","first-page":"1","article-title":"What is neural plasticity?","volume":"Vol 1015","author":"von Bernhardi","year":"2017"},{"key":"10.1016\/j.tips.2025.08.012_bb0500","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pnpbp.2019.01.005","article-title":"Dendritic spines: revisiting the physiological role","volume":"92","author":"Chidambaram","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0505","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.neuron.2018.10.013","article-title":"Activity-regulated transcription: bridging the gap between neural activity and behavior","volume":"100","author":"Yap","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2025.08.012_bb0510","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2025.08.012_bb0515","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neubiorev.2015.06.018","article-title":"Chronic stress and brain plasticity: mechanisms underlying adaptive and maladaptive changes and implications for stress-related CNS disorders","volume":"58","author":"Radley","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.tips.2025.08.012_bb0520","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cns.13622","article-title":"Animal models for the study of depressive disorder","volume":"27","author":"Song","year":"2021","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.tips.2025.08.012_bb0525","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41380-022-01806-1","article-title":"Molecular pathways of major depressive disorder converge on the synapse","volume":"28","author":"Fries","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tips.2025.08.012_bb0530","series-title":"Handbook of Behavioral Neuroscience: Neurobiology of Serotonin","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-444-64125-0.00005-0","article-title":"Classification and signaling characteristics of 5-HT receptors: toward the concept of 5-HT receptosomes","volume":"31","author":"Marin","year":"2020"},{"key":"10.1016\/j.tips.2025.08.012_bb0535","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2025.08.012_bb0540","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1021\/jm00134a016","article-title":"Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy","volume":"24","author":"Migliaccio","year":"1981","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.08.012_bb0545","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201700162","article-title":"Passive membrane penetration of the serotonin precursor 5-hydroxytryptophan is controlled by its zwitterion","volume":"14","author":"Maz\u00e1k","year":"2017","journal-title":"Chem. Biodivers."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725002007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725002007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:41:28Z","timestamp":1762674088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725002007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":109,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0165614725002007"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.08.012","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging mechanisms of psilocybin-induced neuroplasticity","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}